Navigation Links
D-Pharm Receives FDA Clearance to Commence a Phase III Trial of DP-b99 in Acute Stroke Patients
Date:6/8/2009

REHOVOT, Israel, June 8 /PRNewswire/ -- D-Pharm announced today that its Investigational New Drug (IND) application for a pivotal Phase III clinical trial of DP-b99 in acute ischemic stroke patients has been approved by the US Food and Drug Administration (FDA). D-Pharm plans to initiate the trial in the coming months, in over 100 clinical sites in North America, Europe, South Africa and Israel.

The forthcoming Phase III trial is a randomized, double blind, placebo-controlled study (study acronym MACSI: Membrane Activated Chelator Stroke Intervention). It is designed to compare the effect on ischemic stroke outcome between a placebo group and a group of patients treated with 1 mg/kg/day of DP-b99 for 4 consecutive days. D-Pharm plans to enroll 770 moderate to severely affected ischemic stroke patients worldwide, with first patients expected to be recruited in Israel and South Africa.

Dr. Gilad Rosenberg, D-Pharm's VP Clinical Development commented, "The FDA's IND procedure involved review of the entire DP-b99 data set. Following 30 days for review of our IND application, the FDA has no further questions relating to DP-b99's CMC, preclinical and clinical data package. I'm very pleased that the Agency is satisfied with our data and we can move forward with this important study without delay."

Prior to the IND submission D-Pharm successfully completed the program outlined at the pre-IND meeting held with the FDA in January 2008. The program included additional toxicity studies, a drug interaction study with rtPA, and an interaction study with warfarin in healthy volunteers, as well as scale-up and optimization of the DP-b99 manufacturing process.

About DP-b99

DP-b99 is a unique neuroprotective drug that addresses an array of brain damaging processes occurring in stroke patients and emerged from D-Pharm's proprietary Membrane Activated Chelator (MAC) platform technolog
'/>"/>

SOURCE D-Pharm Ltd
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. D-Pharm Secures Funding From Israels Chief Scientists Office
2. D-Pharm Completes Pre-IND Meeting With the FDA for Treatment of Acute Stroke With DP-b99
3. Yongye Biotechnology International Receives License to Manufacture Products
4. EarlySenses EverOn(TM) System Receives FDA Clearance and CE Mark Certification
5. Optimal Reading Services Group, Inc. Receives Investment from Health Evolution Partners
6. Haemonetics Receives Favorable Ruling in Patent Lawsuit against Competitive Technology
7. ViroPharma Receives Complete Response Letter for Cinryze(TM) Supplemental Biologics License Application for Acute Treatment of Hereditary Angioedema
8. Celsense, Inc Receives NIH Grant to Translate Cell Imaging Technology for Clinical Use
9. Mylan Receives Tentative FDA Approval for Generic Version of Singulair(R)
10. 500th Patient Receives Berlin Heart EXCOR Pediatric Ventricular Assist Device
11. SyntheMed Receives Australian Regulatory Approval for REPEL-CV(R)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/13/2014)... The “Global Synthetic Biology Market ... threats, opportunities, and challenges. , The global synthetic ... namely, Thermo Fisher Scientific, Inc. (U.S.), DuPont (U.S.), ... accounted for approximately ~65% of the total synthetic ... for This Report @ http://www.marketsandmarkets.com/Market-Reports/synthetic-biology-market-889.html , ...
(Date:12/13/2014)... , Dec. 12, 2014  Vermillion, Inc. (NasdaqCM: VRML), a ... the appointments of Veronica G. H. Jordan , ... Company,s Board of Directors, bringing the total number of ... Jim LaFrance , Chairman, President, and ... pleased to announce the appointments of Veronica and David ...
(Date:12/13/2014)... RARITAN, N.J. and SAN ANTONIO ... Development, LLC (Janssen) today announced the presentation of data ... the Phase 3 EPO-ANE-3010 study evaluating epoetin alfa plus ... treat anemia in patients with metastatic breast cancer receiving ... primary objective, which was to rule out a 15 ...
(Date:12/12/2014)... Pittsburgh, PA (PRWEB) December 11, 2014 ... 2015 Technical Program that includes over 2,000 ... awards, and posters. This year’s program covers ... not limited to, biotechnology, biomedical, drug discovery, environmental, ... nanotechnology, polymers/plastics, proteomics and water/wastewater. The Technical ...
Breaking Biology Technology:Synthetic Biology Market to HIt $5.6304 Billion by 2018 - New Research Report by MarketsandMakets 2Synthetic Biology Market to HIt $5.6304 Billion by 2018 - New Research Report by MarketsandMakets 3Vermillion Strengthens Board of Directors with Appointments of Veronica Jordan, Ph.D., and David Schreiber 2Vermillion Strengthens Board of Directors with Appointments of Veronica Jordan, Ph.D., and David Schreiber 3Data from the EPO-ANE-3010 Study Evaluating Epoetin Alfa Presented at San Antonio Breast Cancer Symposium 2Data from the EPO-ANE-3010 Study Evaluating Epoetin Alfa Presented at San Antonio Breast Cancer Symposium 3Data from the EPO-ANE-3010 Study Evaluating Epoetin Alfa Presented at San Antonio Breast Cancer Symposium 4Data from the EPO-ANE-3010 Study Evaluating Epoetin Alfa Presented at San Antonio Breast Cancer Symposium 5Data from the EPO-ANE-3010 Study Evaluating Epoetin Alfa Presented at San Antonio Breast Cancer Symposium 6Data from the EPO-ANE-3010 Study Evaluating Epoetin Alfa Presented at San Antonio Breast Cancer Symposium 7Data from the EPO-ANE-3010 Study Evaluating Epoetin Alfa Presented at San Antonio Breast Cancer Symposium 8Data from the EPO-ANE-3010 Study Evaluating Epoetin Alfa Presented at San Antonio Breast Cancer Symposium 9Data from the EPO-ANE-3010 Study Evaluating Epoetin Alfa Presented at San Antonio Breast Cancer Symposium 10Data from the EPO-ANE-3010 Study Evaluating Epoetin Alfa Presented at San Antonio Breast Cancer Symposium 11Data from the EPO-ANE-3010 Study Evaluating Epoetin Alfa Presented at San Antonio Breast Cancer Symposium 12Pittcon Announces a Diverse 2015 Technical Program - Renowned Speakers, Special Symposia and Co-programming 2Pittcon Announces a Diverse 2015 Technical Program - Renowned Speakers, Special Symposia and Co-programming 3
... Company Purchases Two PCT Systems to Help in the Analysis of ... SOUTH EASTON, Mass., Dec. 17 Pressure BioSciences, Inc. ... entered into a collaboration with the J. Craig Venter Institute ("JCVI"), ... MD and La Jolla, CA. As part of the collaboration, ...
... recent customer satisfaction,survey of over 30,000 readers of ADVANCE ... customers as the "Top Of Class" winner for the,microbiology ... ADVANCE chose bioMerieux over other clinical laboratory suppliers,because of ... "quick response time." , ...
... scheduled 16-17 February in Kuala Lumpur, Malaysia, an ... makers have been scheduled. Kicking off the series, ... Pradip Bhar, Chief Executive Officer and Managing Director ... download, this informative interview lends startling insights into ...
Cached Biology Technology:Pressure BioSciences, Inc. and the J. Craig Venter Institute Announce Collaboration Agreement & Purchase of a PCT System 2Pressure BioSciences, Inc. and the J. Craig Venter Institute Announce Collaboration Agreement & Purchase of a PCT System 3Pressure BioSciences, Inc. and the J. Craig Venter Institute Announce Collaboration Agreement & Purchase of a PCT System 4Pressure BioSciences, Inc. and the J. Craig Venter Institute Announce Collaboration Agreement & Purchase of a PCT System 5Laboratory Customers Name bioMerieux 'Top Of Class' for Microbiology 2Jatropha World 2009 Advance Access: Surprisingly Candid Interview Series Examines Biofuel Predictions Compared to Fossil Fuels 2Jatropha World 2009 Advance Access: Surprisingly Candid Interview Series Examines Biofuel Predictions Compared to Fossil Fuels 3Jatropha World 2009 Advance Access: Surprisingly Candid Interview Series Examines Biofuel Predictions Compared to Fossil Fuels 4
(Date:12/11/2014)... , Dec. 10, 2014  That blood pressure plays ... a while. Hypertension – the medical term for high blood ... early 1800s, and the inflatable cuff that,s used in measuring ... however, mean there,s nothing new about hypertension, its triggers and ... beliefs about the condition and the best ways to treat ...
(Date:12/10/2014)... , Dec. 9, 2014  Valencell, a leader ... is seeing a staggering demand from its licensees for ... Company revealed, is not solely coming from fitness and ... well. "A wearable is only as useful ... accuracy is the ultimate driver in long-term mass consumer ...
(Date:12/10/2014)... --Research and Markets ( http://www.researchandmarkets.com/research/xclcvw/biometrics_market ) ... Market in Japan 2014-2018" report to their ... The integration of biometrics and smart ... upgradation of the driver,s license is one of ... the aforementioned projects, biometrics is being used as ...
Breaking Biology News(10 mins):Research points to need for new approaches to treatment of high blood pressure 2Research points to need for new approaches to treatment of high blood pressure 3Research points to need for new approaches to treatment of high blood pressure 4Wearable Technology Products Demand Highly Accurate Biometric Technology 2Biometrics Market in Japan 2014-2018: Key Vendors are DDS, Fujitsu, Hitachi and NEC 2
... (January 28, 2013)A popular dog treat could be adding ... contaminated by bacteria, according to a study published this ... Medicine at Tufts University and the University of Guelph. ... stick." The American and Canadian researchers analyzed the caloric ...
... CORVALLIS, Ore. Dairy cows that are fed flaxseed produce ... State University. Their milk contained more omega-3 fatty acids ... in saturated fat can increase cholesterol and cause heart disease, ... may reduce the risk of heart disease, studies have shown. ...
... in German . , The detector ... has a very low error rate. The results have ... Ultrafast, efficient, and reliable single-photon detectors are among the ... have not yet reached maturity for practical application. Physicist ...
Cached Biology News:Misconceptions about a popular pet treat 2Misconceptions about a popular pet treat 3Cows fed flaxseed produce more nutritious dairy products 2Quantum communication: Each photon counts 2
...
... Characteristics:, Antibody Binding: High, 400 ng ... volume) , Binding Interaction: Hydrophobic/Ionic , Performance ... (bottom): Flat , Maximum Well Volume: 360 ... tray ,Features, Special optically clear ...
...
...
Biology Products: